Pseudophakic Cystoid Macular Edema Associated with Extrafoveal Vitreoretinal Traction

Michael R. Martinez¹ and Avinoam Ophir*¹,²

¹Division of Ophthalmology, Hillel-Yaffe Medical Center, Hadera and ²The Ruth and Bruce Rappaport Faculty of Medicine, The Technion, Haifa, Israel

Abstract: Purpose: To describe an association between extrafoveal vitreoretinal traction and intractable chronic pseudophakic cystoid macular edema (CME) by the use of optical coherence tomography (OCT).

Methods: In a retrospective case series study, charts and OCT findings of patients who had postoperative recalcitrant pseudophakic CME for at least 6 months and vitreoretinal traction membranes were analyzed. Excluded were eyes that either had another vitreoretinopathy that could affect the analysis or had undergone an intravitreal intervention.

Results: Three eyes (three patients) with macular edema following uneventful cataract surgery were detected to be associated with multifocal extrafoveal vitreoretinal traction sites in each. Retinal edema that was underlying each of the traction sites in all eyes was in continuum in at least one site per eye with the central macular edema, thus manifesting as diffuse macular edema.

Conclusion: Chronic pseudophakic macular edema may be related to extrafoveal vitreoretinal traction.

Keywords: Pseudophakic macular edema, macular edema, vitreous traction, extrafoveal traction, OCT.

INTRODUCTION

Cystoid macular edema (CME) is the most common retinal cause of vision impairment after uncomplicated cataract surgery [1]. Pseudophakic CME develops angiographically in up to 20% to 30% of patients after uneventful extracapsular cataract extraction/phacoemulsification, and it usually takes six to eight weeks to develop [2-4]. In most patients, pseudophakic CME resolved spontaneously, with 50% to 75% of patients achieving improved vision within six months. However, clinically significant CME, defined as a Snellen visual acuity of 20/40 or worse, accompanied by cystoid spaces or retinal edema, has been reported to occur in 2.35% of these cases [5].

Most investigators agree that inflammatory mediators (e.g., prostaglandins) and vascular endothelial growth factor (VEGF) may be associated with disruption of the blood-retinal barrier, with resultant fluid accumulation in the perifoveal area [6, 7]. Vitreous traction at the anterior segment structures and ocular hypotony are other factors that have been related to the occurrence of pseudophakic CME [8]. Prompt treatment of the disorder is required since irreversible macular changes might occur if macular edema is present for several months [9]. Several pharmacologic agents are commonly used to treat this condition, including topical, sub-Tenon’s, intravitreal and systemic corticosteroids, as well as oral and topical nonsteroidal anti-inflammatory agents (NSAIDs), but some patients do not respond to these medications [10]. Recently, antiangiogenic agents such as bevacizumab (Avastin) have been implicated in the treatment of pseudophakic CME [11]. However, the benefit of the anti-VEGF agents for pseudophakic CME, which are widely applied for most forms of macular edema is somewhat controversial [11, 12]. In a study that presented a positive beneficial outcome of intravitreal bevacizumab [11], it was so in 72.2% (26/31) of the eyes, but the benefit was, by and large, temporary, whereas the remaining 27.8% did not respond to that therapy. As for surgery, Harbour et al. (n = 24) and Pendergast and associates (n = 23) reported on the outcome of pars plana vitrectomy (PPV) in eyes with recalcitrant pseudophakic CME [13, 14]. In both studies, diminution of the macular edema was substantial, but while there was marked improvement in Snellen best-corrected visual acuity (BCVA) in the former study, it was mild in the latter.

Similarly, refractory chronic macular edema may occur in a variety of other pathologic conditions, such as diabetic retinopathy, retinal vein occlusion (RVO) and posterior uveitis [15-17]. Using optical coherence tomography (OCT), which provides an “optical biopsy” of the macula and the posterior pole in a histological level of resolution, enabled the establishment of vitreofoveal traction as another documented cause of macular edema in these ocular diseases [18]. Recently, vitreous traction membranes that are located extrafoveally, either retinal or at the optic nerve head (ONH; i.e. vitreopapillary traction), have also been found to be associated with macular edema in eyes with diabetic retinopathy using spectral-domain (SD)-OCT [19], as well as in non-diabetic eyes using time-domain (TD)-OCT [20]. The retinal edema that underlined the extrafoveal traction site in these studies was commonly in a continuum with the macular edema, thus presenting as diffuse macular edema.

This study presents (for the first time, to the best of our knowledge; search via Entrez PubMed), a small series of...
Patients in whom chronic macular edema of pseudophakic origin was found to be associated with extrafoveal vitreoretinal traction in each.

**MATERIALS AND METHODOLOGY**

In a retrospective case series study we analyzed the charts and TD-OCT scans (OCT 2000, Humphrey Zeiss Inc., San Leandro, CA, USA), and later the SD-OCT scans (SD-OCT 1000, Topcon Corp., Tokyo, Japan), of patients who had chronic (>6 months) macular edema and vitreoretinal traction following cataract extraction and intraocular lens implantation. Clinical examination included BCVA and slit-lamp and fundus examinations. OCT examination of all eyes was thereafter performed through a dilated pupil by one of two trained examiners.

Using the TD-OCT, evaluation of macular edema was routinely initiated by using the Automatic 6-radial lines program directed to the fixation point and focused on the central macula. This was followed using the Line group program, which the examiner controls manually. Scans were taken at various angles and lengths (a shorter scan increases resolution) to search for a vitreous traction site at both the area centralis (between the vascular arcades) away from the macula and the ONH site. Evidence of traction required vitreous adherence to the retina or ONH associated with, a) tissue elevation and deformity at the traction site, i.e., the shape of the inner retina at the exact site of traction changed its angle and thus was typically thicker than that of the adjoining edematous retinal tissue and, b) the posterior hyaloid or vitreous strand terminated or changed its angle at that site. Vitreous traction at one site (“unifocal”) away from the edematous central macula was designated as “extrafoveal traction”, either at the area centralis (“extrafoveal vitreoretinal” traction) or at the ONH (“vitreopapillary” traction). When there were two or more traction sites, traction was designated as “multifocal”. Vitreous “adherence” (without traction) related to those eyes in which the attachment of the vitreous was not associated with any vitreoretinal or vitreopapillary deformities of these tissues at that site. When an extrafoveal vitreous traction was detected, that site was examined to determine whether or not its underlying retinal edema (or subretinal fluid) was in continuum with the central macular edema.

Using the SD-OCT, 3-dimensional data sets centered on the fovea (6mm X 6mm) were obtained for each patient. As a rule, 3-D data sets were also centered on the ONH in association with the central macula and were obtained using a raster scan program of 8.2 mm (horizontal) x 3 mm (vertical) x 1.7 mm (axial). Volumetric rendering of the data set was performed using image-processing software within the SD-OCT for 3-D image reconstruction. The SD-OCT characteristics are described elsewhere [21]. Data, including the B-mode and 3-D mode, were evaluated later by examining the recorded videos.

Cystoid spaces at the foveal region, as detected by the OCT, were defined as intraretinal round hyporeflective lacunae with well-defined boundaries and hyper-reflective septa separating the cystoid-like cavities. Diffuse macular edema was identified by OCT as an ill-defined and widespread, hyporeflective, increased retinal thickness that often attains the appearance of sponge-like cavities [22, 23]. The 6-mm Early Treatment Diabetic Retinopathy Study (ETDRS) macular maps and the OCT false-colors maps provided quantitative and qualitative information on the thickness of the retinal tissue at the site in question, respectively, and were quantitatively compared with the normal controls. We used our normative TD-OCT (n = 12) and SD-OCT (n = 50) database of normal macular thickness in age-matched patients as controls. Based on these, macular thickness using TD-OCT or SD-OCT was considered thickened when its central sub-field (CST) exceeded 200 μm (TD-OCT) or 250 μm (SD-OCT), similar to data previously reported [24, 25]. The fovea could be designated as edematous when cystoid spaces were located at its site, even if the tissue was not abnormally thickened, due to the fact that it could be thin due to atrophy or lamellar hole formation.

Patients were included in the study if they had both chronic macular edema (>6 months) that appeared following cataract extraction and was related to vitreoretinal traction membranes. Exclusion criteria covered eyes that had: 1) another retinopathy that could affect the data analysis; 2) chronic uveitis; 3) vitreoretinal adherence without signs of retinal traction or vitreous traction without macular edema; 4) undergone vitreoretinal surgery; 5) been treated by intravitreal administration of medication(s), or 6) eyes in which the OCT scans were of too low a quality for a proper diagnosis and measurements.

Research adhered to the tenets of the Declaration of Helsinki, and the approval of the Institutional Review Board was obtained.

**RESULTS**

Three patients, aged 51-78 years old, with chronic pseudophakic CME in one eye, in which any other potential

| Table 1. Data of Patients with Pseudophakic Cystoid Macular Edema |
|-------------------|-----------------|-----------------|-----------------|
| **Patient** | **A/G/E** | **BCVA** | **Central Sub-Field Thickness (in Microns)** | **Site of Extrafoveal Traction** | **Comments** |
| 1 | 89/F/LE | 20/80 | 340 | Three sites: 1-2) sites infero-nasal to fovea; 3) at the vitreopapillary site |
| 2 | 64/M/LE | 20/60 | 285 | Two sites: 1) Inferior to the optic nerve head; 2) Inferonasal to fovea | Pseudohole |
| 3 | 53/M/RE | 20/60 | 370 | Two sites: 1) At the papillomacular bundle; 2) superotemporal to the fovea |

A=Age, G=Gender, E=Eye; BCVA=Best-corrected visual acuity; M=Male, F=Female; RE=Right eye; L=Left eye.
clinical cause for the edema was not detected, were diagnosed using OCT to have extrafoveal multifocal vitreoretinal traction sites in each eye. Patients’ characteristics and OCT findings are summarized in Table 1. Both the B-mode video clips of the SD-OCT and their 3-D image reconstructions enabled fast and unambiguous detection of extrafoveal traction membranes in eyes No. 1 & 2 (Figs. 1, 2). The retinal edema that underlined each of the vitreoretinal traction sites in Eye No. 1, including the edema that was associated with the vitreopapillary traction, was in continuum with the central macular edema, thus attaining a pattern of diffuse macular edema. This observation could be depicted from the macular maps and the 3-D image reconstructions of the SD-OCT (Fig. 1 and supplementary video clip 1). Eye No. 2 had Irvine-Gass syndrome with a swollen disc at the early postoperative period. Four years later, using SD-OCT, the perifoveal area was mildly thickened, and a pseudohole at the central macula with adjacent ERM was apparent. The retinal edema that underlined one of the two detectable traction sites was in continuum with the central macular edema in that eye (Fig. 2).

---

**Fig. (1).** Extrafoveal multifocal vitreoretinal traction and pseudophakic macular edema as detected by the spectral-domain OCT (Pt. 1). A + B. The clinical picture and macular map (the right circle map below the fundus picture) illustrate macular edema located centrally and inferonasally to the fovea (purple color). The yellow squares in A and B delineate the scanned area (6 x 6 mm). C + D. The B-mode presents two extrafoveal vitreoretinal traction membranes, marked by arrowhead in C and by an arrow in D. The manually marked vertical yellow lines indicate the traction sites; the OCT software automatically marks the anatomical locations in blue crosses, in A & B. Each of the underlying retinal edema sites (asterix) is in continuum with the central macula (seen in the map in A & B). E. 3-D image reconstruction reveals a relatively thick connection between the two vitreoretinal traction membranes associated with diffuse macular edema (asterix); the purple vertical line marks the foveal site. The arrowhead shows the inferior membrane (shown at C) and the arrow shows the superior one (shown in D). F. 3-D image reconstruction (area of 8.2 mm X 3 mm) includes the macula (the fovea is marked by the purple line), the superior traction site (arrow) and the optic nerve head (ONH; star). Multifocal vitreous membranes are associated with the ONH.
The third eye (No. 3) was examined by TD-OCT (OCT-2000) and presented with diffuse macular edema accompanied by cystoid spaces. Vitreoretinal traction membranes were identified at two sites, one parafoveally at the papillomacular bundle (PMB) zone and the second temporally to the fovea (Fig. 3; a 3-D image reconstruction is not available in the TD-OCT). The centrally fixed Automatic 6-radial lines program of the OCT-2000 enabled the diagnosis of extrafoveal vitreous traction, which was located parafoveally at the PMB site. A small area of subretinal fluid underlined this traction site. The second traction site in this eye was detected by the Line group program, but not by the Automatic 6-radial lines program. The retinal edema that underlined each of the two detected traction sites was in direct communication with the edema at the central macula. This observation could be depicted from the OCT B-mode and the macular map (Fig. 3C, D).

Fig. (2). Extrafoveal multifocal vitreoretinal traction associated with pseudophakic CME as detected by the SD-OCT (Pt. 2). A + B. The clinical picture and the accompanying small false-color map (below the fundus picture), as detected by 8.2mm X 3 mm scan area (the colored rectangle) illustrate macular edema (red and yellow colors). The blue crosses, one in A and one in B, demonstrate two extrafoveal vitreoretinal traction sites. One retinal edema site (in B) is shown by the false-color map to be in continuum with the central macula. C + D. The B-mode (C) and the 3-D image reconstruction (D) reveal two sites under traction by one continuous vitreous membrane (arrow). Each traction site is manually marked by a vertical white line, and its retinal location is shown automatically by yellow crosses in A & B. The optic nerve (ON) is seen in D.

DISCUSSION

The study presents three eyes with refractory pseudophakic diffuse macular edema that was associated with multifocal extrafoveal vitreoretinal traction in each. The retinal edema that was underlying at least one traction site per eye was in continuum with the macula, manifesting in each as diffuse macular edema.

Several studies on PPV for treating recalcitrant pseudophakic CME have been published [13, 14, 26]. Harbour et al. reported on 24 consecutive patients who underwent PPV for chronic pseudophakic CME that failed to respond medically [13]. The surgery resulted in improved visual acuity in all eyes from a mean visual acuity of 20/190 preoperatively to 20/52 postoperatively, with a mean improvement of 4.7 Snellen lines. Peyman et al. reported on the beneficial effect of PPV and internal limiting membrane
peeling, which took place in two eyes with recalcitrant pseudophakic CME 11-22 months after cataract surgery [26].

By contrast, Pendergast et al. reported the results of PPV for intractable chronic pseudophakic CME in 23 consecutive eyes with no apparent vitreoretinal disturbance. Surgery resulted in resolution of the CME in all cases, though with improved visual acuity in only some of the eyes [14]. This relatively low functional benefit could be related to the macular edema's having been present for a mean of 20 months (range, 3-110 months) prior to surgery. The suggestion of that possibility is based on earlier studies on PPV for diabetic macular edema (DME) [27, 28], which suggest that a delay in performing surgery may partly explain the permanently reduced vision in spite of marked structural improvement [27]. Other authors who found PPV for DME of benefit attributed it in part to the removal of growth factors associated with macular edema from the vitreous site [29]. However, the studies on PPV for pseudophakic CME did not mention or rule out an existence of extrafoveal vitreous traction, and the stated cause of surgery's success or failure of the surgery was often ambiguous. The presence of extrafoveal vitreous traction in the current study may be relevant to that issue.

The centrally fixated Automatic 6-radial lines program of the TD-OCT (OCT-2000) enabled unequivocal diagnosis of one site of vitreous traction in eye No. 3, which was located parafoveally at the PMB site (Fig. 3). Only the Line group program enabled the detection of the second traction site in this eye. As previously described, detection of extrafoveal traction can often be made only with the Line group or the Raster line programs [30]. This is due to the fact that the length of each scan in the Automatic 6-radial lines program is 5.9 mm, the scans are separated from each other by a 30° arc and program’s output is limited to the 6 lines that are scanned. Furthermore, the length of the arc between two adjacent radial lines at their farthest point from the center is >1.5 mm (2πR/12 = 2 X 3.14 X 3 / 12). Therefore, using the Line scan or the Raster line programs to search for an extrafoveal site is likely to require hundreds of scan lines in order to cover every point at the area centralis. As a consequence, many extrafoveal traction sites may be overlooked due to omission of vitreous adherence sites that are typically small, because of progressive patient fatigue in

---

**Fig. (3).** Extrafoveal multifocal vitreoretinal traction associated with pseudophakic CME as detected by a time-domain OCT (Pt. 3). (A) Vitreous traction membrane (asterix) located at the papillomacular bundle area, in proximity to the ONH (not shown). An underlying localized subretinal fluid (star) and a diffuse macular edema are associated with the traction membrane. (B) A second vitreoretinal traction membrane (arrowhead) is located temporosuperiorly to the fovea; a retinal edema underlies it. (C) The 6-mm false-color and quantitative thickness macular maps disclose diffuse macular edema associated with two different traction sites (marked by arrowhead and asterix). The central sub-field thickness is 370 μm. (D) The quantitative macular map of the normal controls (n = 12).
this time-consuming search, and because of progressive corneal epithelial drying that could result in poor scan quality.

In contrast, two eyes (No. 1 & 2) were plainly diagnosed to have multifocal extrafoveal traction membranes by the SD-OCT. With a scanning time of 3.7 seconds, the SD-OCT detected extrafoveal traction sites much faster than the TD-OCT did, and is also expected to have a higher rate of accuracy than the TD-OCT does [31]. That is, since the SD-OCT screens every point at the scanned vitreous membranes and retinal surface, acquiring an entire A-scan simultaneously, its B-mode has 40,000 A-scans per second (vs 400 A-scans/second in the TD-OCT), and it promises image acquisition at 50 to 100 times the TD-OCT speed with equal or improved spatial resolution. In addition, the improved 6µm axial resolution of the SD-OCT over the TD-OCT (10-15µm) allows better identification of morphologic details in the retina and the vitreoretinal interface, as previously described [32, 33]. The 3-D image reconstruction of the SD-OCT may provide more detailed information than its B-mode can because it reveals a real image, both horizontally and vertically, of the whole vitreoretinal area under study with better spatial perception of the vitreoretinal interface. Such an image is depicted, for example, in Fig. (I) and supplementary video clip No. 1.

Except for the potential for consideration of PPV in these eyes, detection of extrafoveal traction should also be important if a therapeutic agent like bevacizumab or triamcinolone acetonide (kenalog) is planned intravitreally, since doing so can result in worsening of traction and subsequent traction retinal detachment [34].

Limitations of the study refer to its retrospective design and small series. However, the study raises the possibility that recalcitrant pseudophakic CME or macular edema may be associated with extrafoveal vitreoretinal traction. The SD-OCT detected the traction sites much faster and with a higher rate of confidence than the TD-OCT could. Further studies and a larger cohort are required to validate whether early vitrectomy is the treatment of choice in these situations.

**VIDEO CLIP NO. 1 (PATIENT NO. 1)**

This article also contain supplementary material (3-D movie clip) ans it can be viewed at publisher’s website.

The 3-D movie shows 2 continuous vitreoretinal traction sites. Each of the traction sites is underlain by retinal edema that is in continuum with the central macula, thus presenting as diffuse macular edema (see also Fig. I).

**REFERENCES**

[1] Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg 1995; 21: 59-63.
[2] Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998; 96: 557-634.
[3] Stark WJ Jr, Maumenee AE, Fagadu W, et al. Cystoid macular edema in pseudophakia. Surv Ophthalmol 1984; 28 (Suppl):442-51.
[4] Jampol LM. Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema. 1985 update. Ophthalmology 1985; 92: 807-10.
[5] Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg 2007; 33: 1550-8.
[6] Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47(Suppl 1): S203-18.
[7] Kent D, Vinores SA, Camachoario PA. Macular oedema: the role of soluble mediators. Br J Ophthalmol 2000; 84: 542-5.
[8] Stenos PG, Wicksremasinghe SS, Stagos NT, Topouzis F, Tsipoulous I, Pavesio CE. Macular edema. Surv Ophthalmol 2004; 49: 470-90.
[9] Reis A, Birnbaum F, Hansen LL, Reinhard T. Successful treatment of cystoid macular edema with valdecoxib. J Cataract Refract Surg 2007; 33: 682-5.
[10] Rho DS. Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolac. J Cataract Refract Surg 2003; 29: 2378-84.
[11] Arevalo JF, Maia M, Garcia-Amaris RA, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology 2009; 116: 1481-7.
[12] Spitznag MS, Ziemssen F, Petermeier K, Aisenbrey S, Szurnez P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008; 34: 70-5.
[13] Harbour JW, Smiddy WE, Rubsam PE, Murray TG, Davis JL, Flynn HW Jr. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. Am J Ophthalmol 1995; 120: 302-7.
[14] Pendergast SD, Margherio RR, Williams GA, Cox MS Jr. Vitrectomy for chronic pseudophakic cystoid macular edema. Am J Ophthalmol 1999; 128: 317-23.
[15] Gass JD. A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. IV. Diabetic retinal angiopathy. Arch Ophthalmol 1968; 80: 583-91.
[16] Hayreh SS, Hayreh MS. Hemi-central retinal vein occlusion: Pathogenesis, clinical features, and natural history. Arch Ophthalmol 1980; 98:1600-9.
[17] Rosoff A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol 2007; 18:487-92.
[18] Pufilaffio CA, Hac MR, Schumam JS, Fujimoto JO, Eds. Diabetic retinopathy. In: Optical Coherence Tomography of Ocular Diseases. Thorofare, NJ, Slack Inc, 1996; pp. 127-60.
[19] Ophir A, Trevino A, Martinez MR. Extrafoveal vitreous traction associated with branch retinal vein occlusion. Eur J Ophthalmol 2010; 20: 733-9.
[20] Fatum S, Trevino A, Ophir A. Non-diabetic diffuse macular edema associated with extrafoveal vitreous traction. Isr Med Assoc J 2009; 11: 286-90.
[21] Hangai M, Ojima Y, Gotoh N, et al. Three-dimensional imaging of macular holes with high-speed optical coherence tomography. Ophthalmology 2007; 114: 763-73.
[22] Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005; 140: 200-6.
[23] Yamamoto S, Yamamoto T, Hayashi M, Takeuchi S. Morphological and functional analyses of diabetic macular oedema by optical coherence tomography and multifocal electroretinograms. Graefes Arch Clin Exp Ophthalmol 2001; 239: 96-101.
[24] Massin P, Vicaud E, Hauuchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001; 119: 1135-42.
[25] Sayanagi K, Sharma S, Kaised PK. Comparison of retinal thickness measurements between three-dimensional and radial scans on spectral-domain optical coherence tomography. Am J Ophthalmol 2009; 148: 431-8.
[26] Peyman GA, Canakis C, Livir-Rallatos C, Conway MD. The effect of internal limiting membrane peeling on chronic recalcitrant pseudophakic cystoid macular edema: a report of two cases. Am J Ophthalmol 2002; 133: 571-2.
[27] La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol 2001; 239: 264-70.
[28] Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2004; 242: 630-7.
[29] Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-9.
[30] Ophir A, Trevino A, Fatum S. Extrafoveal vitreous traction associated with diabetic diffuse macular oedema. Eye (Lond) 2010; 24: 347-53.

[31] Koizumi H, Spaide RF, Fisher YL, Freund KB, Klancnik JM Jr, Yannuzzi LA. Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 145: 509-17.

[32] Geitzenauer W, Kiss CG, Durbin MK, et al. Comparing retinal thickness measurements from Cirrus spectral domain- and Stratus time domain-optical coherence tomography. Retina 2010; 30: 596-606.

[33] Gupta V, Gupta P, Singh R, Dogra MR, Gupta A. Spectral-domain Cirrus high-definition optical coherence tomography is better than time-domain Stratus optical coherence tomography for evaluation of macular pathologic features in uveitis. Am J Ophthalmol 2008; 145:1018-22.

[34] Arevalo JF, Maia M, Flynn HW, Jr., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213-6.